Price movement over the last 24 hours
ADMA Biologics Inc vs Global X Copper Miners ETF — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while Global X Copper Miners ETF trades at $72.69. The key difference: Global X Copper Miners ETF is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | COPX | |
|---|---|---|
Market Cap | $2.13B | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $20.38 | $95.70 |
52-Week Low | $7.60 | $42.75 |
Enterprise Value | $2.20B | — |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
COPX (Global X Copper Miners ETF) trades at $78.48, up 2.39% with a bullish technical signal despite mixed moving averages. The ETF provides diversified exposure to copper mining companies benefiting from AI-driven copper demand growth. Recent news highlights copper's structural deficit and AI infrastructure needs as key catalysts. Technical indicators show RSI_12 at 24.51 (buy signal) while ADX suggests strong trend momentum.
Outlook remains positive given copper's essential role in AI infrastructure and electrification trends. Key risks include copper price volatility and supply chain constraints. The ETF offers leveraged exposure to copper prices through mining equities, with support at $76 and resistance at $79-80 levels.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →COPX tracks the Solactive Global Copper Miners Total Return Index, providing broad exposure to companies worldwide involved in copper mining, refining, and exploration. It serves as an equity-based alternative to copper futures, offering a leveraged play on copper demand driven by global infrastructure and the clean energy transition.
Read more on COPX →